The Atrantil Pro formula is a combination of two clinically studied GI support supplements, balanced for optimal restoration and protection of digestive function.* This combination is the most studied comprehensive OTC option for health professionals.

What is Atrantil PRO?

Atrantil Polyphenols

Methane

Harmful bacteria

 NFKB

TNF-Alpha

Chronic inflammatory pathways

Hydrogen sulfide

Anti-oxidants

Anti-aging

SIRT1 pathway

NRF2 pathway

Short chain fatty acids (Butyrate, Propionate, etc)

Helpful bacteria, including Akkermansia muciniphila

 Microbial diversity

 

Mega trio Spore Biotic

B subtilis, B coagulans, B clausii

Inflammatory markers (IL6)

 Intestinal permeability (leaky gut)

LPS signaling

Harmful bacteria

NFKB

TNF-Alpha

Chronic inflammatory pathways

SCFA Butyrate

 SCFA Propionate

 Microbial Diversity

**Key for Antibiotic associated

    Dysbiosis    

 Helpful bacteria, including Akkermansia muciniphila

Become an Atrantil-PRO Retailer

Become an Atrantil PRO Retailer

If you’re ready to give your patients the latest in efficacy and safety for bloating and abdominal discomfort accompanied by constipation, diarrhea or both, the Atrantil team’s here to help.

Fill out this form or call 214-984-3724 ext. 708

These statements have not been evaluated the Food and Drug Administration.  This product is not intended to diagnose, treat, cure, prevent any disease.


RESULTS PROVEN IN CLINICAL RESEARCH

Dr. Kenneth Brown and his team created Atrantíl based on their understanding of how its three main natural botanicals would work together to relieve bloating, abdominal discomfort, and changes in bowel habits—constipation, diarrhea, or both. And to prove their formula was more than just a good idea, they tested it twice with real patients.


DOUBLE-BLIND TRIAL In a double-blind study of patients suffering from bloating, constipation and abdominal discomfort, Atrantíl proved to be more than 88 percent effective in relieving symptoms. The leading two prescription therapies didn’t perform as well versus a placebo according to their own studies. The results of the trial were published in the Journal of Gastroenterology and Hepatology Research – September 21, 2015 pp. 1762-1767.

OPEN-LABEL TRIAL The open-label trial targeted the toughest-to-treat patients to illustrate the efficacy of Atrantíl. Before beginning the trial, patients qualified to participate only after failing to find relief from at least four prescription therapies. The trial showed that 80 percent of patients found relief after using Atrantíl to control their bloating, constipation and abdominal discomfort. The results of the trial were published in the World Journal of Gastrointestinal Pharmacology and Therapeutics – August 6, 2016 pp. 463-468.

ATRANTIL FOR INTESTINAL BACTERIAL OVERGROWTH TRIAL  Atrantil is currently the focus of a trial being conducted by Northwestern University. More information on this trial can be found here.

See Clinical Research Results